LillyDirect (Zepbound) tirzepatide: price, structure, and position (2026)

LillyDirect (Zepbound)↗ charges $449 a month all-in for compounded tirzepatide at the 10 mg maintenance basis, up from an advertised $299 entry point, with no membership fee — ranking #null of 17 verified programs (captured 2026-08-09).

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

SOURCE-VERIFIED · captured 2026-08-09 · source

§ The tirzepatide record, in words

What LillyDirect (Zepbound) bills for tirzepatide, exactly

LillyDirect (Zepbound)’s tirzepatide program bills $449 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $299, but the maintenance figure — the one a full year is actually billed at — is $449. That $150 gap between the ad and the anniversary is the single most important line in this record.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $449 is the whole subscription, which makes LillyDirect (Zepbound) unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #0 of 17 in the verified tirzepatide index — $234/month above the floor (NexLife↗, $215) — and sits $0 over the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $5,388.

Tirzepatide, across time

The same $449 figure, stretched across the horizons people actually budget for:

1 month: $449 billed monthly. 3 months: $1,347 billed monthly; no prepaid term is published at this horizon, so monthly billing is the only path. 6 months: $2,694 billed monthly; no prepaid term is published at this horizon, so monthly billing is the only path. 9 months: $4,041 billed monthly; no prepaid term is published at this horizon, so monthly billing is the only path. 12 months: $5,388 billed monthly; no prepaid term is published at this horizon, so monthly billing is the only path. 18 months: $8,082 billed monthly; no prepaid term is published at this horizon, so monthly billing is the only path. 24 months: $10,776 billed monthly; no prepaid term is published at this horizon, so monthly billing is the only path.

Remember what the arithmetic cannot know: whether you will tolerate the medication, whether the dose will move (financially decisive here, since pricing is tiered), and whether the program’s terms will hold. The calculator reruns all of this at your inputs.

Where this price sits — tirzepatide

In the tirzepatide index, LillyDirect (Zepbound) ranks #null of 17 verified programs — $234 a month above the floor (NexLife, $215) and $148 under the ceiling (LifeMD↗, $597). Against the approved product: Zepbound (LillyDirect) runs $449 at maintenance, so LillyDirect (Zepbound) is $0 a month over brand — at which point the compounded lane needs a reason beyond price; note the maintenance figure holds only with refills inside Lilly’s 45-day window.

Against the five nearest rivals — tirzepatide

Eden costs $41 less a month ($492/year) at $408 ($99/mo membership inside its figure, tiered/step structure). MEDVi costs $50 less a month ($600/year) at $399 (no membership, dose-flat). Remedy Meds costs $50 less a month ($600/year) at $399 (no membership, dose-flat). Fridays costs $90 less a month ($1,080/year) at $359 (no membership, dose-flat). Lavender Sky Health costs $97 less a month ($1,164/year) at $352 ($25/mo membership inside its figure, tiered/step structure).

Operationally: Shipping is included (or same-day retail pickup), so the door-to-door figure is the advertised figure; consultation is bring your own prescription (telehealth partners available); labs are not required to enroll (a prescriber can still order them for cause, which is medicine, not upsell); the visit model is prescription required. Commitment: 45-day refill cadence to keep pricing; cancellation: no subscription; refill-window rules apply. Fulfillment is unusually checkable: LillyDirect (Zepbound) names its pharmacy network — Eli Lilly direct / retail partners (manufacturer direct) — which means a careful reader can verify licenses with state boards and, for 503B facilities, the FDA’s registration list. Most of this market refuses that test.

Where these numbers come from: source-verified, last read 2026-08-09 from the provider’s published pages. Every figure above traces to a dated capture; when the provider’s page changes, the database changes, and the diff lands in the changelog. If any number here no longer matches what LillyDirect (Zepbound) publishes, tell the desk — confirmed errors are fixed sitewide in one rebuild and logged permanently.

§ Adjacent pages